Back to Search Start Over

Gestion pratique des inhibiteurs de PARP : Un consensus national DELPHI

Authors :
Frédéric Selle
Jean-Jacques Boffa
Gabriel Etienne
Antoine Angelergues
Paule Augereau
Dominique Berton
Pascale Dielenseger
Michel Fabbro
Claire Falandry
Philippe Follana
Laurence Gladieff
Florence Joly
Jean-Emmanuel Kurtz
Carla Matta
Marie-Ange Mouret-Reynier
Antonin Schmitt
Florian Scotté
Coralie Marjollet
Anne Floquet
Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN)
Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Imagerie Moléculaire et Stratégies Théranostiques (IMoST)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)
Source :
Bulletin du Cancer, Bulletin du Cancer, 2022, 109 (12), pp.1245-1261. ⟨10.1016/j.bulcan.2022.06.011⟩
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

International audience; Objective > Despite an increasing number of therapeutic indications, there are no specific recommendations regarding the management of PARP inhibitors other than what is specified in the SmPC of each substance. A Delphi French consensus was conducted to establish practical guidelines to meet the needs identified by healthcare professionals and patients. Method > Following the Delphi method, statements to optimize PARP inhibitor management were drafted by a multidisciplinary Steering Committee made up of 17 experts. These statements were submitted to the independent and anonymous vote of clinicians involved in treating patients on PARP inhibitors. Results > This article presents 52 statements on the following topics: initiation and treatment; management of adverse events (hematological effects, gastrointestinal effects, renal effects, pulmonary effects, cutaneous effects, hypertension, insomnia, fatigue, dizziness); special popu-lations and situations; communication with the patient; adherence. Forty-nine statements obtained voter consensus after 3 voting rounds. A hematologist and a nephrologist supplemented this task by drafting an expert opinion on the risk of occurrence of secondary leukemia and nephrological toxicity. Conclusions > This paper is the first Delphi consensus on the practical management of PARP inhibitors. The pragmatic recommendations resulting from this paper should make it possible to manage the side effects of PARP inhibitors better and thus prevent early treatment discontinua-tion and improve patient adherence by preserving quality of life.

Details

ISSN :
00074551 and 17696917
Volume :
109
Database :
OpenAIRE
Journal :
Bulletin du Cancer
Accession number :
edsair.doi.dedup.....d38da6de81fcf50c3bcc907750c3952c
Full Text :
https://doi.org/10.1016/j.bulcan.2022.06.011